Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Additional Information (Details)

v3.23.2
Fair Value Measurements - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]          
Estimated fair value of equity securities $ 33,349   $ 33,349   $ 32,020
Unrealized gain (loss) on equity securities 8,321 $ (3,736) 1,329 $ (3,173)  
Vaxcyte, Inc. | Vaxcyte Common Stock          
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]          
Estimated fair value of equity securities 33,300   33,300   $ 32,000
Unrealized gain (loss) on equity securities $ 8,300 $ (3,700) $ 1,300 $ (3,200)  
Vaxcyte, Inc. | Equity Securities | Vaxcyte Common Stock          
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]          
Number of shares held 667,780   667,780   667,780
Fair Value Measurements Recurring          
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]          
Securities held $ 391,155   $ 391,155   $ 330,430